4
|
Schnadig I, Agajanian R, Dakhil S, Taylor C, Wilks S, Cooper W, Mosier M, Payne Y, Klepper M, Vacirca J. Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Managing delayed chemotherapy-induced nausea and vomiting (CINV) associated with HEC is an unmet need. AC-based HEC is often administered to breast cancer patients (pts), a mostly female, high-CINV-risk population. APF530, an extended-release formulation of granisetron, demonstrated superior complete response (CR; no emesis [vomiting, retching] + no rescue medication use) in delayed-phase (>24-120 h) CINV with HEC (ASCO criteria) vs ondansetron (Ond) (65% vs 57%, P=0.014), each combined with a neurokinin-1 antagonist and dexamethasone (Dex) (NCT02106494). This post hoc analysis evaluated efficacy and safety of APF530 in pts receiving AC-based therapy.
Methods: In this randomized, double-blind, multicenter trial, pts scheduled to receive single-day HEC were stratified by cisplatin ≥50 mg/m2 yes/no and randomized 1:1 to APF530 500 mg SC (granisetron 10 mg) or Ond 0.15 mg/kg IV. Pts received concomitant Dex 12 mg IV and fosaprepitant 150 mg IV on day 1 and oral Dex on days 2-4. The primary end point was CR in the delayed phase. Secondary and other end points included CR in acute (0-24 h) and overall (0-120 h) phases, and complete control (CC; CR and no more than mild nausea) and total response (TR; CR and no nausea) in acute, delayed, and overall phases. Rates were compared using 95% confidence intervals (CIs) for treatment differences; post hoc analysis was not powered to detect treatment differences in the AC subgroup. Safety assessments included adverse events (AEs), injection-site reactions (ISRs), laboratory parameters, and vital signs.
Results: A total of 589/902 pts (65%) in the modified intent-to-treat population received AC-based HEC (APF530 291, Ond 298). Baseline demographics were balanced between treatment arms. The majority of pts in the AC subgroup were female (APF530 99%, Ond 98%). Delayed-phase CR was higher with APF530 vs Ond, approaching statistical significance (APF530 64%, Ond 56%; P=0.062) in the AC subgroup, similar to the benefit seen in the larger study. No appreciable benefit of APF530 vs Ond was observed in the acute phase, and trends favorable to APF530 were observed in the overall phase (Table). APF530 was well tolerated. Most AEs were ISRs, generally mild or moderate, and resolved by end of study.
Phase, n (%)APF530OndansetronTreatment DifferenceN=291N=298(95% CI), %Complete responseDelayed185 (64)167 (56)8 (-0.4, 15.4)Overall163 (56)153 (51)5 (-3.4, 12.7)Acute205 (70)204 (69)1 (-5.4, 9.4)Complete controlDelayed171 (59)156 (52)7 (-1.6, 14.4)Overall149 (51)143 (48)3 (-4.9, 11.3 )Acute193 (66)191 (64)2 (-5.5, 9.9)Total responseDelayed119 (41)107 (36)5 (-2.9, 12.8)Overall100 (34)94 (32)2 (-4.8, 10.4)Acute164 (56)173 (58)-2 (-9.7, 6.3)
Conclusions: APF530 demonstrated an apparent clinical benefit in delayed-phase CR in pts receiving AC-based HEC, concordant with the statistically significant benefit seen in the overall study population. Prevention of CINV in this patient population continues to be a treatment challenge and further investigation is needed.
Citation Format: Schnadig I, Agajanian R, Dakhil S, Taylor C, Wilks S, Cooper W, Mosier M, Payne Y, Klepper M, Vacirca J. Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-07.
Collapse
Affiliation(s)
- I Schnadig
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - R Agajanian
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - S Dakhil
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - C Taylor
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - S Wilks
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - W Cooper
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - M Mosier
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - Y Payne
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - M Klepper
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| | - J Vacirca
- Compass Oncology, US Oncology Network, Tualatin, OR; The Oncology Institute of Hope and Innovation, Whittier, CA; Cancer Center of Kansas, Wichita, KS; Tulsa Cancer Institute, Tulsa, OK; Cancer Care Centers of South Texas, San Antonio, TX; TFS International, Flemington, NJ; EMB Statistical Solutions, LLC, Overland Park, KS; Heron Therapeutics, Redwood City, CA; Drug Safety Navigator, LLC, Durham, NC; North Shore Hematology Oncology, East Setauket, NY
| |
Collapse
|
6
|
Patt D, Espirito J, Turnwald B, Denduluri N, Wang Y, Lina A, Hoverman R, Neubauer M, Bosserman L, Busby L, Brooks B, Cartwright T, Sitarik M, Schnadig I, Winter W, Garey J, Ginsburg-Arlen A, Bergstrom K, Beveridge R. Abstract P2-11-16: Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early Breast Cancer in the Community Setting. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-11-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cardiac morbidity after exposure to CT is a known and previously described risk. Anthracycline exposure can be complicated by acute or chronic cardiac toxicity. Trastuzumab exposure is largely associated with acute and reversible cardiac morbidity.
Methods: We retrospectively queried the electronic health record (EHR) from our network of community oncology practices, iKnowMed, for patients (pts) diagnosed with Stage I-III breast cancer (BC) from 2007–2010 with at least 5 visits and follow-up (f/u) through 2012. We stratified this group by CT utilization (yes/no), regimen type, age, and characterized the incidence of cardiac disease or initiation of cardiac medication through the f/u period to determine the association of cardiac disease or treatment with CT utilization. Cardiac diseases analyzed included congestive heart failure, valvular and ischemic heart disease, arrythmias, and hypertension. Cardiac medications included beta blockers, angiotensin-converting-enzyme inhibitors, angiotensin receptor II blockers, loop and thiazide diuretics. Hazard ratios by prespecified risk parameters were then analyzed by multivariate analysis for all pts who did not have cardiac disease preceding their diagnosis of BC.
Results: We identified 20,900 pts with a median f/u of 3.2 yrs (1.4–5.4). 11,295 (54%) pts received adjuvant CT and 9,605 (46%) did not. Median age at diagnosis in the CT-treated arm and non CT-treated arm was 54 and 64 yrs, respectively (p < 0.0001). Among both the non-CT and CT-treated group, the baseline prevalence of cardiac disease was 14%. Among the CT-treated group, 3475 pts or 31% (95% CI, 30 %−32%) had or developed cardiac disease within the study period. In the non-CT group, 3790 pts or 39% (95% CI, 38%−40%) had or developed cardiac disease with the study period (p < 0.01). Receiving CT conveyed a lower risk of cardiac morbidity overall, HR 0.86 (p < 0.01). Incidence of cardiac disease was higher among pts who were in the non-CT treated arm (39%) than among the various CT-treated arms: anthracycline and trastuzumab (30%), anthracycline without trastuzumab (26%), non-anthracycline with trastuzumab (33%), and non-anthracycline without trastuzumab (34%). Incidence of cardiac disease increased proportionally over time in all age groups as expected in both cohorts.
Conclusions: Age was a strong determinant of development of cardiac morbidity. Adjuvant CT did not increase the risk of cardiac morbidity compared to pts who did not receive CT in the community setting. Similarly, anthracycline and trastuzumab exposure did not increase cardiac morbidity when compared to no CT or other CT regimen types. While baseline cardiac comorbid illness was similar among both cohorts, the lack of increase in cardiac morbidity among pts who received CT may be due to confounding factors such as comorbid illness and age as they are often determinants of appropriate CT utilization.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-16.
Collapse
Affiliation(s)
- D Patt
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - J Espirito
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - B Turnwald
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - N Denduluri
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - Y Wang
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - A Lina
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - R Hoverman
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - M Neubauer
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - L Bosserman
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - L Busby
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - B Brooks
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - T Cartwright
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - M Sitarik
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - I Schnadig
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - W Winter
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - J Garey
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - A Ginsburg-Arlen
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - K Bergstrom
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| | - R Beveridge
- Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR
| |
Collapse
|